微RNA-21在神经胶质瘤患者脑脊液中的水平及意义

The level and its clinical significance of microRNA-21 in cerebrospinal fluid of glioma patients

目的探讨微RNA．21（miR．21）在神经胶质瘤患者脑脊液中的水平及其临床意义。方法采用实时定量反转录聚合酶链反应（RT—PCR）检测40例神经胶质瘤患者（神经胶质瘤组）及40例健康人（对照组）脑脊液中miR．21水平，并分析miR．21水平与神经胶质瘤病理分级之间的关系。结果神经胶质瘤组脑脊液中miR．21相对表达水平为0．70±0．12，与对照组的0．43±0．09比较明显升高，差异有统计学意义（t=11．3840，P〈0．01）。神经胶质瘤病理分级Ⅱ、Ⅲ、Ⅳ级患者分别有16、13、11例，脑脊液中miR-21相对表达水平分别为0．66±0．11、0．71±0．12、0．74±0．13，差异无统计学意义（F=1．5083，P=0．2345）。结论神经胶质瘤患者脑脊液中miR．21水平增高，miR-21可能参与了神经胶质瘤的发生、发展过程。

Objective To explore the level and its clinical significance of microRNA-21 （miR-21 ） in cerebrospinal fluid of glioma patients. Methods The level of miR-2l in cerebrospinal fluid were measured by real-time RT-PCR in 40 patients with glioma （glioma group ） and 40 normal controls （control group）. The relationship between miR-21 and pathological grade were analyzed. Results The level of miR-21 in glioma group was significantly higher than that in control group （0.70 ± 0.12 vs. 0.43 ±0.09,t = 11.3840, P 〈 0.01 ）. The level of miR-21 in glioma group with II , III and IV pathological grade was 0.66 ± 0.11,0.71 ± 0.12,0.74 ±0.13, there was no significant difference （F = 1.5083, P = 0.2345 ）. Conclusions The level of miR-21 in cerebrospinal fluid of glioma patients elevates significantly. It may participate in the occurrence and development of glioma.